GNR-055 在 II 型粘多糖贮积症患者中的安全性、有效性、PK 和 PD 的多队列研究
评估药物产品 GNR 055(JSC“GENERIUM”,俄罗斯)在 II 型粘多糖贮积症患者中的安全性、药代动力学、药效学和疗效的多中心、开放标签、多队列研究
This is phase 2/3 study to evaluate the safety, pharmacokinetics, pharmacodynamics, and efficacy of the investigational product GNR-055 in MPS II (Hunter syndrome) patients of different age groups.
研究概览
地位
详细说明
GNR-055 is intended for ERT in patient with Mucopolysaccharidosis type II (MPS II), or Hunter syndrome. MPS II is a recessive X-linked inheritance lysosomal storage disease, which is characterized by a deficiency of the lysosomal enzyme iduronate-2-sulfatase (ID2S), caused by a mutation in the ID2S gene. Enzyme deficiency leads to the accumulation of Glycosaminoglycans (GAG) (mainly of heparan and dermatan sulfates) in lysosomes of almost all types of cells of various tissues and organs. The disease is manifested by growth retardation, damage of many organs and systems, severe deformations of bones and joints, gross facial features, pathology of the respiratory and cardiovascular systems, damage to parenchymal organs (hepatosplenomegaly), and hearing impairment. A severe form of the disease occurs with the involvement of the nervous system in the pathological process, including mental retardation, behavior anomalies, and impaired motor function.
GNR-055 is a recombinant modified ID2S capable to penetrate the blood-brain barrier and thus expected to prevent neurodegenerative consequences and the cognitive deficit and to attain a significant improvement in the life quality and expectancy of patients with MPS II.
Study IDB-MPS-II-III is a multicenter, open-label, multi-cohort study to assess safety, PK and PD, and efficacy of GNR-055 in patients of different age groups with MPS II (Hunter syndrome).
研究类型
注册 (估计的)
阶段
- 阶段2
- 第三阶段
联系人和位置
学习地点
-
-
-
Moscow、俄罗斯、119333
- Federal State-Funded Healthcare Institution Central Clinical Hospital of the Russian Academy of Sciences (Research Institute of Pediatrics and Child Health Protection of the Central Clinical Hospital of the Russian Academy of Sciences)
-
Saint Petersburg、俄罗斯、194100
- Federal State Budgetary Educational Institution of Higher Education "St. Petersburg State Pediatric Medical University" of the Ministry of Health of the Russian Federation
-
Simferopol、俄罗斯、295007
- V.I. Vernadsky Crimean Federal University
-
Ufa、俄罗斯、450076
- State Budgetary Healthcare Institution Republican Medical Genetic Center
-
Yekaterinburg、俄罗斯、620149
- State Autonomous Healthcare Institution of the Sverdlovsk Region Regional Children's Clinical Hospital
-
-
参与标准
资格标准
适合学习的年龄
- 孩子
- 成人
- 年长者
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Signed inform consent;
- Verified diagnosis of MPS II (Hunter syndrome);
- Naïve patients or patients who have received standard ERT whit idursulfase products;
- No contraindications for lumbar puncture as judged by the Investigator;
- Willingness and ability to follow study procedures.
Exclusion Criteria:
- Clinically pronounced hypersensitivity to ID2S or any other component of the drug product;
- History of hematopoietic stem cell transplantation (HSCT) or bone marrow transplantation;
- Implanted or external non-removable metal devices, a cardiac pacemaker, or other objects sensitive to the magnetic field that may pose a danger to both the wearer and the correct operation of magnetic resonance imaging (MRI) equipment;
- Concomitant diseases and conditions that, in the Investigator's opinion, can put at risk the patient's safety during his/her participation in the study, or which will influence the safety data analysis in case of the disease/condition exacerbation during the study.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:非随机化
- 介入模型:顺序分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Adult: GNR-055
GNR-055: 1.0-2.0-3.0 mg/kg |
Weekly IV infusion (lyophilized powder) 1.0-2.0-3.0 mg/kg
其他名称:
|
|
实验性的:Paediatric: GNR-055 2.0 mg/kg
GNR-055 2.0 mg/kg |
Weekly IV infusion (lyophilized powder) 2.0 mg/kg
其他名称:
|
|
实验性的:Paediatric: GNR-055 3.0 mg/kg
GNR-055 3.0 mg/kg |
Weekly IV infusion (lyophilized powder) 3.0 mg/kg
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Incidence of Adverse events (AEs) and Serious Adverse Events (SAEs)
大体时间:Baseline to Week 56
|
Safety assessment will be performed based on the subjective complaints, physical examination, assessment of vital signs, laboratory tests, and 12-lead ECG; Incidence of allergic and infusion-related reactions; Incidence of Anti-Drug Antibodies (ADAs) against GNR-055 and their neutralizing activity. |
Baseline to Week 56
|
|
Urine GAG excretion
大体时间:Baseline to Week 4, 8, 10, 26, and 52
|
Changes in levels of urine GAG excretion after multiple-dose administration of GNR-055 |
Baseline to Week 4, 8, 10, 26, and 52
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Serum concentration of the GNR-055
大体时间:Week 52
|
Assessment of the serum concentration of GNR-055 and calculation of Cmax, AUC, T1/2, Cl et other parameters after multiple-dose administration |
Week 52
|
|
GAG level in CerebroSpinal Fluid (CSF)
大体时间:Baseline to Week 6, 10, 26, and 52
|
Changes in levels of CSF GAG after multiple-dose administration of GNR-055 |
Baseline to Week 6, 10, 26, and 52
|
|
Serum GAG level
大体时间:Baseline to Week 4, 8, 10, 26, and 52
|
Changes in levels of serum GAG after multiple-dose administration of GNR-055 |
Baseline to Week 4, 8, 10, 26, and 52
|
|
Large joint range of motion
大体时间:Week 8, 10, 26, and 52
|
Changes over time in the large joint range of motion after multiple-dose administration of GNR-055 |
Week 8, 10, 26, and 52
|
|
Liver and spleen volumes (MRI)
大体时间:Baseline to Week 8, 10, 26, and 52
|
Changes over time in liver and spleen volume according to ultrasound/MRI after multiple-dose administration of GNR-055 |
Baseline to Week 8, 10, 26, and 52
|
|
6-minute walk test
大体时间:Baseline to Week 8, 10, 26, and 52
|
Changes over time in the results of the 6-minute walk test after multiple-dose administration of GNR-055 |
Baseline to Week 8, 10, 26, and 52
|
|
Left ventricular mass by EchoCG
大体时间:Baseline to Week 8, 10, 26, and 52
|
Changes over time in the left ventricular mass according to Echocardiography (Echo-CG) after multiple-dose administration of GNR-055 |
Baseline to Week 8, 10, 26, and 52
|
|
Lung Forced Vital Capacity (FVC)
大体时间:Baseline to Week 8, Week 26, and Week 52
|
Changes over time in FVC according to spirometry after multiple-dose administration of GNR-055 |
Baseline to Week 8, Week 26, and Week 52
|
|
Neurocognitive functions assessment
大体时间:Baseline to Week 12, 26, and 52
|
Changes over time in neurocognitive functions after multiple-dose administration of GNR-055 |
Baseline to Week 12, 26, and 52
|
|
Brain white/gray matter structures (MRI)
大体时间:Baseline to Week 26, and 52
|
Changes over time in the quantitative MRI brain structure parameters after multiple-dose administration of GNR-055 |
Baseline to Week 26, and 52
|
|
Serum neuromarkers
大体时间:Baseline to Week 24, and 52
|
Changes in levels of serum neuromarkers after multiple-dose administration of GNR-055 |
Baseline to Week 24, and 52
|
|
CSF neuromarkers
大体时间:Baseline to Week 24, and 52
|
Changes in levels of CSF neuromarkers after multiple-dose administration of GNR-055 |
Baseline to Week 24, and 52
|
合作者和调查者
赞助
调查人员
- 研究主任:Oksana A. Markova, MD, MSc、AO GENERIUM
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
关键字
其他相关的 MeSH 术语
其他研究编号
- IDB-MPS-II-III
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.